Haemonetics Corporation (HAE) Q2 2027 Earnings Call Transcript
Haemonetics Corporation (HAE) Q2 2027 Earnings Call Transcript
Seeking Alpha11/5/2026Neutral
HAE
Haemonetics CorporationNYSEHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$5.46B
P/E Ratio
53.07
EPS
$2.26
Beta
0.59
52W High
$132.00
52W Low
$51.00
50-Day MA
$111.47
200-Day MA
$79.91
Dividend Yield
—
Profit Margin
7.52%
Forward P/E
23.58
PEG Ratio
1.97
About Haemonetics Corporation
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $1.38B |
| Gross Profit (TTM) | $827.69M |
| EBITDA | $361.21M |
| Operating Margin | 21.00% |
| Return on Equity | 11.90% |
| Return on Assets | 6.64% |
| Revenue/Share (TTM) | $30.07 |
| Book Value | $19.74 |
| Price-to-Book | 6.28 |
| Price-to-Sales (TTM) | 3.95 |
| EV/Revenue | 4.709 |
| EV/EBITDA | 22.72 |
| Quarterly Earnings Growth (YoY) | 23.50% |
| Quarterly Revenue Growth (YoY) | 9.30% |
| Shares Outstanding | $45.50M |
| Float | $44.93M |
| % Insiders | 1.26% |
| % Institutions | 110.34% |
Historical Volatility
HV 10-Day
39.66%
HV 20-Day
31.88%
HV 30-Day
54.05%
HV 60-Day
50.36%
HV Rank
88.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($124.50 target)
4
Strong Buy5
Buy2
HoldLatest News
Haemonetics Corporation (HAE) Hits Fresh High: Is There Still Room to Run?
Haemonetics (HAE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Research11/5/2026Positive
Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.3 per share. This compares to earnings of $1.27 per share a year ago.
Zacks Investment Research11/5/2026Positive
Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, Nov. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2027, which ended September 26, 2026, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
PRNewsWire11/5/2026Neutral
GEHC vs. HAE: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Haemonetics (HAE). But which of these two stocks is more attractive to value investors?
Zacks Investment Research10/29/2026Positive
All You Need to Know About Haemonetics (HAE) Rating Upgrade to Buy
Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research10/27/2026Positive
Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update
The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exelixis rounded out our top contributors.
Seeking Alpha10/27/2026Neutral
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
Zacks Investment Research10/20/2026Positive
Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
BOSTON, Oct. 19, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of the PerQseal® Elite vascular closure system for large-bore arterial procedures. The approval expands Haemonetics' portfolio of clinically-differentiated large-bore closure devices for structural heart and endovascular procedures in the U.S., following the company's acquisition of Vivasure Medical Limited in January 2026.
PRNewsWire10/19/2026Neutral
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.
Zacks Investment Research10/16/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HAE and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026